NCT03259568 is a NA clinical trial of Repetitive TMS in Human Brain Activity, sponsored by Duke University.

Who is sponsoring NCT03259568?

NCT03259568 is sponsored by Duke University.

What drugs are being tested in NCT03259568?

Interventions in NCT03259568: Repetitive TMS.

What condition does NCT03259568 study?

NCT03259568 studies Human Brain Activity.

Is NCT03259568 still recruiting?

NCT03259568 is currently terminated. Last updated 29 March 2023.

Are results published for NCT03259568?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-03-29 · How we verify

NCT03259568

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of rTMS on Human Brain Activity Measured With fMRI

Terminated NA Results posted Last updated 29 March 2023

What this trial tests

NA trial testing Repetitive TMS in Human Brain Activity in 27 participants. Terminated before completion.

Timeline

12 January 2018

Primary endpoint
20 August 2019

20 August 2019

Quick facts

Lead sponsor	Duke University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	factorial
Masking	single
Primary purpose	basic science
Enrollment	27
Start date	12 January 2018
Primary completion	20 August 2019
Estimated completion	20 August 2019
Sites	1 location across United States

Drugs / interventions tested

Repetitive TMS

Conditions studied

Human Brain Activity — all drugs for Human Brain Activity →

Sponsor

Duke University

Who can join

Adults 18 to 30, any sex, with Human Brain Activity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Motion Perception Accuracy Primary · during each TMS session, up to 3 hours

Acute effect of a rTMS session on the performance for a motion task, as measured by accuracy (in percentage of correct responses)

Group	Value	95% CI
Dose-response TMS - Intensity = 20%RMT	63	± 4.0
Dose-response TMS - Intensity = 40%RMT	62	± 4.0
Dose-response TMS - Intensity = 80%RMT	58	± 4.0
Dose-response TMS - Intensity = 120%RMT	61	± 3.0

Reaction Time Primary · during each TMS session, up to 3 hours

Acute effect of a rTMS session on the performance for a motion task, as measured by reaction time (in ms)

Group	Value	95% CI
Dose-response TMS - Intensity = 20%RMT	814	± 104
Dose-response TMS - Intensity = 40%RMT	784	± 94
Dose-response TMS - Intensity = 80%RMT	762	± 85
Dose-response TMS - Intensity = 120%RMT	810	± 109

Activation of Cortical Networks During a Visual Motion Task. Primary · during each TMS session, up to 3 hours

Acute effect of a rTMS session on fMRI activation during a motion task, as measured by the change in BOLD signal

Group	Value	95% CI
Dose-response TMS - Intensity = 20%RMT	0.89	± 0.06
Dose-response TMS - Intensity = 40%RMT	0.87	± 0.05
Dose-response TMS - Intensity = 80%RMT	0.88	± 0.06
Dose-response TMS - Intensity = 120%RMT	0.94	± 0.04

Sponsor's own description

This project investigates the effects of repetitive transcranial magnetic stimulation (rTMS) on neural circuits as a function of spatiotemporal parameters and brain state in order to better understand why the method works and how to improve its efficacy. Leveraging our expertise in application of TMS methodology during concurrent single neuron recording techniques in non-human primates and imaging and scalp potential techniques in humans, the investigators aim to resolve three interlocking problems in the design and application of rTMS: stimulation frequency, spatial targeting, and interactions with brain state.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Repetitive TMS

Trials testing the same drug.

NCT03628703 — Response Inhibition in Tourette Syndrome · NA · completed

Other Duke University trials

Trials by the same sponsor.

NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03259568 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03259568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing